{
  "id": 15869752,
  "title": "Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?",
  "url": "https://urgent.news/2026/10/21/alnylam-is-now-solidly-profitable-why-are-investors-treating-it-like",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-21T08:44:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/21/alnylam-is-now-solidly-profitable-why-are-investor/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": null,
  "summary": "This beaten-down biotech has a better story than its stock chart suggests.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}